Diagnostics
Study finds demand for effective prognosis spurs uptake of molecular diagnostics
Published in Medical Letter on the CDC and FDA, October 31st, 2004
As participants continue to become ever more conscious of its high-tech appeal, their initial hesitation to diverge from an established practice is likely to decrease.
New analysis from Frost & Sullivan, U.S. Molecular Diagnostics Markets, reveals that revenue in this market totaled $1.22 billion in 2004 and is projected to reach $3.68 billion in 2010.
"Though physicians are rather wary of adopting new techniques, the growing number of clinical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Diabetes Genomics and Genetics
DRB1*030101 alleles outside of exon 2 not linked to type 1 diabetes - Prostate Cancer
Proteomics applied to prostate cancer biomarker discovery and detection - Streptococcus
Group G streptococcal bacteremia reported in Jerusalem - Streptococcus
Model system for growing Streptococcus pneumoniae biofilms developed - AIDS/HIV Vaccine
Pathogenic SHIVs and SIVs target different CD4+ T cell subsets - Adverse Drug Effect
Dantrolene and chlorzoxazone linked to rare serious hepatotoxicity - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
